RxDoctor Payments Data

Kevin Schmitz

Physician Assistant · Fort Worth, TXNPI 1376020842

Payments from drug & device makers

$8,364in general payments, 2019–2025

Across 323 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Johnson & Johnson$843
  • Astellas Pharma US Inc$750
  • Endo Pharmaceuticals Inc.$489
  • Dendreon Pharmaceuticals LLC$420
  • Sumitomo Pharma America, Inc.$312
  • plus $4K from 39 others

What the payments were for

  • Travel & lodging$260%
  • Food & beverage$7,87194%
  • Education$4676%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,364 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$503,249
Medicare patients
449
Services billed
17,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron151$130,091
GemtesaVibegron56$47,415
JatenzoTestosterone Undecanoate14$14,598
Testosterone Cypionate219$12,974
XyostedTestosterone Enanthate20$12,424
Testosterone31$10,574
Mirabegron ErMirabegron11$7,258
Solifenacin Succinate128$6,693
Tamsulosin Hcl439$4,639
Estradiol55$3,553
NitrofurantoinNitrofurantoin Macrocrystal93$2,319
Trospium Chloride ErTrospium Chloride12$2,127
Fosfomycin Tromethamine11$2,043
Potassium Citrate ErPotassium Citrate28$1,959
Finasteride189$1,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$750$130,091151 claims
Sumitomo Pharma America, Inc.Gemtesa$312$47,41556 claims
Clarus Therapeutics Inc.Jatenzo$217$14,59814 claims
Antares Pharma, Inc.Xyosted$267$12,42420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →